Literature DB >> 21636553

Role of CXCR3 ligands in IL-7/IL-7R alpha-Fc-mediated antitumor activity in lung cancer.

Asa Andersson1, Minu K Srivastava, Marni Harris-White, Min Huang, Li Zhu, David Elashoff, Robert M Strieter, Steven M Dubinett, Sherven Sharma.   

Abstract

PURPOSE: We evaluated the utility of chimeric γc homeostatic cytokine, IL-7/IL-7Rα-Fc, to restore host APC (antigen presenting cell) and T cell activities in lung cancer. EXPERIMENTAL
DESIGN: Utilizing murine lung cancer models we determined the antitumor efficacy of IL-7/IL-7Rα-Fc. APC, T cell, cytokine analyses, neutralization of CXCL9, CXCL10, and IFNγ were carried out to evaluate the mechanistic differences in the antitumor activity of IL-7/IL-7Rα-Fc in comparison to controls.
RESULTS: IL-7/IL-7Rα-Fc administration inhibited tumor growth and increased survival in lung cancer. Accompanying the tumor growth inhibition were increases in APC and T cell activities. In comparison to controls, IL-7/IL-7Rα-Fc treatment of tumor bearing mice led to increased: (i) levels of CXCL9, CXCL10, IFNγ, IL-12 but reduced IL-10 and TGFβ, (ii) tumor macrophage infiltrates characteristic of M1 phenotype with increased IL-12, iNOS but reduced IL-10 and arginase, (iii) frequencies of T and NK cells, (iv) T cell activation markers CXCR3, CD69 and CD127(low), (v) effector memory T cells, and (vi) T cell cytolytic activity against parental tumor cells. IL-7/IL-7Rα-Fc treatment abrogated the tumor induced reduction in splenic functional APC activity to T responder cells. The CXCR3 ligands played an important role in IL-7/IL-7Rα-Fc-mediated antitumor activity. Neutralization of CXCL9, CXCL10, or IFNγ reduced CXCR3 expressing activated T cells infiltrating the tumor and abrogated IL-7/IL-7Rα-Fc-mediated tumor growth inhibition.
CONCLUSIONS: Our findings show that IL-7/IL-7Rα-Fc promotes afferent and efferent antitumor responses in lung cancer. ©2011 AACR.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21636553      PMCID: PMC3118413          DOI: 10.1158/1078-0432.CCR-10-3346

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  56 in total

Review 1.  Interleukin-7: an interleukin for rejuvenating the immune system.

Authors:  Richard Aspinall; Sian Henson; Jeffrey Pido-Lopez; Pa Tamba Ngom
Journal:  Ann N Y Acad Sci       Date:  2004-06       Impact factor: 5.691

2.  Effects of IL-7 and IL-2 on highly enriched CD56+ natural killer cells. A comparative study.

Authors:  B Naume; T Espevik
Journal:  J Immunol       Date:  1991-10-01       Impact factor: 5.422

Review 3.  Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes.

Authors:  Alberto Mantovani; Silvano Sozzani; Massimo Locati; Paola Allavena; Antonio Sica
Journal:  Trends Immunol       Date:  2002-11       Impact factor: 16.687

Review 4.  Lymphocyte lifespans: homeostasis, selection and competition.

Authors:  A A Freitas; B B Rocha
Journal:  Immunol Today       Date:  1993-01

5.  Intratumoral administration of dendritic cells overexpressing CCL21 generates systemic antitumor responses and confers tumor immunity.

Authors:  Seok-Chul Yang; Sven Hillinger; Karen Riedl; Ling Zhang; Li Zhu; Min Huang; Kimberly Atianzar; Brian Y Kuo; Brian Gardner; Raj K Batra; Robert M Strieter; Steven M Dubinett; Sherven Sharma
Journal:  Clin Cancer Res       Date:  2004-04-15       Impact factor: 12.531

6.  Critical role for CXCR3 chemokine biology in the pathogenesis of bronchiolitis obliterans syndrome.

Authors:  John A Belperio; Michael P Keane; Marie D Burdick; Joseph P Lynch; Ying Ying Xue; Kewang Li; David J Ross; Robert M Strieter
Journal:  J Immunol       Date:  2002-07-15       Impact factor: 5.422

7.  Identification of human cancers deficient in antigen processing.

Authors:  N P Restifo; F Esquivel; Y Kawakami; J W Yewdell; J J Mulé; S A Rosenberg; J R Bennink
Journal:  J Exp Med       Date:  1993-02-01       Impact factor: 14.307

8.  Extra-lymphatic solid tumor growth is not immunologically ignored and results in early induction of antigen-specific T-cell anergy: dominant role of cross-tolerance to tumor antigens.

Authors:  Alex Cuenca; Fengdong Cheng; Hongwei Wang; Jason Brayer; Pedro Horna; Lingping Gu; Harold Bien; Ivan M Borrello; Hyam I Levitsky; Eduardo M Sotomayor
Journal:  Cancer Res       Date:  2003-12-15       Impact factor: 12.701

9.  Interleukin 7 generates antitumor cytotoxic T lymphocytes against murine sarcomas with efficacy in cellular adoptive immunotherapy.

Authors:  D L Jicha; J J Mulé; S A Rosenberg
Journal:  J Exp Med       Date:  1991-12-01       Impact factor: 14.307

10.  SLC/CCL21-mediated anti-tumor responses require IFNgamma, MIG/CXCL9 and IP-10/CXCL10.

Authors:  Sherven Sharma; Seok-Chul Yang; Sven Hillinger; Li X Zhu; Min Huang; Raj K Batra; Jeff F Lin; Marie D Burdick; Robert M Strieter; Steven M Dubinett
Journal:  Mol Cancer       Date:  2003-04-15       Impact factor: 27.401

View more
  24 in total

Review 1.  Myeloid suppressor cells and immune modulation in lung cancer.

Authors:  Minu K Srivastava; Åsa Andersson; Li Zhu; Marni Harris-White; Jay M Lee; Steven Dubinett; Sherven Sharma
Journal:  Immunotherapy       Date:  2012-03       Impact factor: 4.196

Review 2.  CXCR3 in carcinoma progression.

Authors:  Bo Ma; Ahmad Khazali; Alan Wells
Journal:  Histol Histopathol       Date:  2015-02-09       Impact factor: 2.303

3.  Myeloid-restricted ablation of Shp2 restrains melanoma growth by amplifying the reciprocal promotion of CXCL9 and IFN-γ production in tumor microenvironment.

Authors:  P Xiao; Y Guo; H Zhang; X Zhang; H Cheng; Q Cao; Y Ke
Journal:  Oncogene       Date:  2018-05-24       Impact factor: 9.867

Review 4.  CXCL9, CXCL10, CXCL11/CXCR3 axis for immune activation - A target for novel cancer therapy.

Authors:  Ryuma Tokunaga; Wu Zhang; Madiha Naseem; Alberto Puccini; Martin D Berger; Shivani Soni; Michelle McSkane; Hideo Baba; Heinz-Josef Lenz
Journal:  Cancer Treat Rev       Date:  2017-11-26       Impact factor: 12.111

5.  Adenosine A2B receptor blockade slows growth of bladder and breast tumors.

Authors:  Caglar Cekic; Duygu Sag; Yuesheng Li; Dan Theodorescu; Robert M Strieter; Joel Linden
Journal:  J Immunol       Date:  2011-11-23       Impact factor: 5.422

6.  Systemic administration of TLR3 agonist induces IL-7 expression and IL-7-dependent CXCR3 ligand production in the lung.

Authors:  Jun-O Jin; Qing Yu
Journal:  J Leukoc Biol       Date:  2012-12-27       Impact factor: 4.962

7.  GITR agonist enhances vaccination responses in lung cancer.

Authors:  Li X Zhu; Michael Davoodi; Minu K Srivastava; Puja Kachroo; Jay M Lee; Maie St John; Marni Harris-White; Min Huang; Robert M Strieter; Steven Dubinett; Sherven Sharma
Journal:  Oncoimmunology       Date:  2015-04-27       Impact factor: 8.110

Review 8.  IL-7 in human health and disease.

Authors:  Wangko Lundström; Natasha M Fewkes; Crystal L Mackall
Journal:  Semin Immunol       Date:  2012-03-10       Impact factor: 11.130

9.  Interleukin (IL)-7 Signaling in the Tumor Microenvironment.

Authors:  Iwona Bednarz-Misa; Mariusz A Bromke; Małgorzata Krzystek-Korpacka
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

10.  Genome-scale analysis of DNA methylation in lung adenocarcinoma and integration with mRNA expression.

Authors:  Suhaida A Selamat; Brian S Chung; Luc Girard; Wei Zhang; Ying Zhang; Mihaela Campan; Kimberly D Siegmund; Michael N Koss; Jeffrey A Hagen; Wan L Lam; Stephen Lam; Adi F Gazdar; Ite A Laird-Offringa
Journal:  Genome Res       Date:  2012-05-21       Impact factor: 9.043

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.